{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:52Z","timestamp":1790867152723,"version":"4.1.0"},"reference-count":193,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"Marie Sk\u0142odowska-Curie Actions"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2021,1,2]]},"DOI":"10.1080\/17425255.2021.1836158","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T03:15:30Z","timestamp":1602472530000},"page":"23-39","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":53,"title":["Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6478-1959","authenticated-orcid":false,"given":"Anne-Grete","family":"M\u00e4rtson","sequence":"first","affiliation":[{"name":"University Medical Center Groningen, University of Groningen","place":["Groningen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gena","family":"Burch","sequence":"additional","affiliation":[{"name":"University of Florida","place":["Gainesville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Ghimire","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen","place":["Groningen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen","place":["Groningen, The Netherlands"]},{"name":"Westmead Hospital","place":["Sydney, Australia"]},{"name":"The University of Sydney","place":["Sydney, Australia"]},{"name":"University of Sydney","place":["Sydney, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"University of Florida","place":["Gainesville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,8]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2016.1162785"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0222-8"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262150-00001"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0803"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.19.0025"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"e_1_3_4_9_1","unstructured":"WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019 [Internet]. Geneva; 2019 [cited 2020 Sep 21]. Available from: https:\/\/www.who.int\/tb\/publications\/2019\/consolidated-guidelines-drug-resistant-TB-treatment\/en\/."},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/322706"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinms.2018.10.002"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00177"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211797470192"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181cc6d6f"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00384-19"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00092-12"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30079-6"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu1146"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01285-2015"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00040-2016"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-18"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.03.017"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa420"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01092-18"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0475"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.064527"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-18"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-09"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz942"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12780"},{"key":"e_1_3_4_33_1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/cid\/ciy346","article-title":"Intermediate susceptibility dose-dependent breakpoints for high-dose rifampin, isoniazid, and pyrazinamide treatment in multidrug-resistant tuberculosis programs","volume":"67","author":"Zuur MA","year":"2018","unstructured":"Zuur MA, Pasipanodya JG, van Soolingen D, et al. Intermediate susceptibility dose-dependent breakpoints for high-dose rifampin, isoniazid, and pyrazinamide treatment in multidrug-resistant tuberculosis programs. Clin Infect Dis an off Publ Infect Dis Soc Am. 2018;67:1743\u20131749.","journal-title":"Clin Infect Dis an off Publ Infect Dis Soc Am"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1429-9"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00763-3"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.04.019"},{"key":"e_1_3_4_37_1","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) [Internet]","author":"WHO","year":"2017","unstructured":"WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) [Internet]. 2017 [cited 2020 Sep 21]. Available from: https:\/\/www.who.int\/tb\/publications\/2017\/dstb_guidance_2017\/en\/"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2083-4"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky152"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-5994.2003.00390.x"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05792-11"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01733779"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2011.12.001"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-15"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.8.1237"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1086\/508278"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528020-00003"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200311-1612OC"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/429321"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.634"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1086\/496980"},{"key":"e_1_3_4_55_1","first-page":"1360","article-title":"Pharmacokinetics of ethambutol in children and adults with tuberculosis","volume":"8","author":"Zhu M","year":"2004","unstructured":"Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis off J. Int Union against Tuberc Lung Dis. 2004;8:1360\u20131367.","journal-title":"Int J Tuberc Lung Dis off J"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141002"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1086\/651377"},{"key":"e_1_3_4_58_1","first-page":"967","article-title":"Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects","volume":"12","author":"Hasenbosch RE","year":"2008","unstructured":"Hasenbosch RE, Alffenaar JWC, Koopmans SA, et al. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int J Tuberc Lung Dis off J Int Union against Tuberc Lung Dis. 2008;12:967\u2013971.","journal-title":"Int J Tuberc Lung Dis off J"},{"key":"e_1_3_4_59_1","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang Y","year":"2003","unstructured":"Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis off J. Int Union against Tuberc Lung Dis. 2003;7:6\u201321.","journal-title":"Int J Tuberc Lung Dis off J"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1231-1"},{"key":"e_1_3_4_61_1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/j.1875-9114.1998.tb03138.x","article-title":"Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids","volume":"18","author":"Peloquin CA","year":"1998","unstructured":"Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy. 1998;18:1205\u20131211.","journal-title":"Pharmacotherapy."},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_3_4_63_1","doi-asserted-by":"crossref","unstructured":"East\u00a0African-British Medical Research\u00a0Councils. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. 1974;2:237\u2013240.","DOI":"10.1016\/S0140-6736(74)91411-1"},{"key":"e_1_3_4_64_1","first-page":"1079","article-title":"Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis","volume":"1","year":"1972","unstructured":"Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1972;1:1079\u20131085.","journal-title":"Lancet"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01681-08"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00176610"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy609"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01036-07"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00064-11"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1086\/605576"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202411"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00343-17"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu572"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy611"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1086\/424849"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.10.012"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2292-x"},{"key":"e_1_3_4_78_1","first-page":"2018 Sep 24;62(","article-title":"Increased doses lead to higher drug exposures of Levofloxacin for treatment of tuberculosis","author":"Peloquin CA","unstructured":"Peloquin CA, Phillips PPJ, Mitnick CD, et al. Increased doses lead to higher drug exposures of Levofloxacin for treatment of tuberculosis. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e00770\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811867"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12147"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx317"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku171"},{"key":"e_1_3_4_84_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/cid\/civ921","article-title":"Pharmacokinetics of Bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis","author":"Akkerman OW","year":"2016","unstructured":"Akkerman OW, Odish OFF, Bolhuis MS. et al. Pharmacokinetics of Bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin Infect Dis an off Publ Infect Dis Soc Am United States. 2016; 523\u2013524.","journal-title":"Clin Infect Dis an off Publ Infect Dis Soc Am United States"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix992"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01908-2019"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.639"},{"key":"e_1_3_4_88_1","article-title":"Impact of Rifabutin or Rifampin on Bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers","author":"Healan AM","unstructured":"Healan AM, Griffiss JM, Proskin HM, et al. Impact of Rifabutin or Rifampin on Bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e00855\u20131717.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0615"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1500286"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035114"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2016.1225498"},{"key":"e_1_3_4_94_1","unstructured":"Zyvox 600 mg film-coated tablets summary of product characteristics [Internet]. 2018 [cited 2020 Sep 21]. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/9857#gref."},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00015"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000597"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00001913"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.11.012"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.09.051"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00751-17"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.017"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01741-15"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky096"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02185-2015"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00580-2019"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy625"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw417"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102500513"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198916020-00002"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa310"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0267-y"},{"key":"e_1_3_4_113_1","first-page":"63","article-title":"Clofazimine induced cardiotoxicity\u2013a case report","volume":"66","author":"Choudhri SH","year":"1995","unstructured":"Choudhri SH, Harris L, Butany JW, et al. Clofazimine induced cardiotoxicity\u2013a case report. Lepr Rev. 1995;66:63\u201368.","journal-title":"Lepr Rev"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.024"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1159\/000221787"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0268"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0648"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy624"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00055-19"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00860-8"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0863"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21498"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30100-2"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.03.036"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01207-9"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00798-13"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03332-14"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02632-12"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy613"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.06.008"},{"key":"e_1_3_4_132_1","first-page":"85","article-title":"Nephrotoxicity induced by gentamicin and amikacin","volume":"142","author":"Smith CR","year":"1978","unstructured":"Smith CR, Maxwell RR, Edwards CQ, et al. Nephrotoxicity induced by gentamicin and amikacin. Johns Hopkins Med J. 1978;142:85\u201390.","journal-title":"Johns Hopkins Med J"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.1.147"},{"key":"e_1_3_4_134_1","first-page":"2017 Feb 23;61(","article-title":"Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis","author":"van Altena R","unstructured":"van Altena R, Dijkstra JA, van der Meer ME, et al. Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e01400\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00962-16"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00961-16"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1086\/420742"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-15"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"e_1_3_4_140_1","first-page":"1382","article-title":"Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative","volume":"8","author":"Nathanson E","year":"2004","unstructured":"Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. [Internet]. 2004;8:1382\u20131384. Available from:: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15581210","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_4_141_1","first-page":"1161","article-title":"Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis","volume":"13","author":"Lee HW","year":"2009","unstructured":"Lee HW, Kim DW, Park JH, et al. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis [Internet]. 2009;13:1161\u20131166. Available from:: https:\/\/pubmed.ncbi.nlm.nih.gov\/19723408.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.810-814.2001"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1054\/tube.2002.0330"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2015.56.4.961"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00713-20"},{"key":"e_1_3_4_146_1","unstructured":"WHO treatment guidelines for drug-resistant tuberculosis. 2016 Update [Internet]. 2020 Aug 20 [cited 2020 Sep 21];64(9):e00713\u201320. Available from: https:\/\/apps.who.int\/medicinedocs\/en\/m\/abstract\/Js23097en\/."},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00263-7"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2015.78.2.78"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.3.9807131"},{"key":"e_1_3_4_150_1","volume-title":"Drug-resistant tuberculosis: a survival guide for clinicians","author":"Curry International Tuberculosis Center and California Department of Public Health","year":"2016","unstructured":"Curry International Tuberculosis Center and California Department of Public Health. 2016. Drug-resistant tuberculosis: a survival guide for clinicians. 3rd ed. California, USA: Curry International Tuberculosis Center.","edition":"3"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03073-14"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx306"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx022"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc6818"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2014.94"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks395"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv170"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1701102"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01654-2015"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02039-16"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02250-17"},{"key":"e_1_3_4_162_1","doi-asserted-by":"crossref","first-page":"e01489","DOI":"10.1128\/AAC.01489-18","article-title":"Evaluation of Carbapenems for treatment of multi- and extensively drug-resistant mycobacterium tuberculosis","volume":"63","author":"van Rijn SP","year":"2019","unstructured":"van Rijn SP, Zuur MA, Anthony R, et al. Evaluation of Carbapenems for treatment of multi- and extensively drug-resistant mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019;63:e01489\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030373"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00214-2016"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268814002970"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2019.197664"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(09)60400-9"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01215-19"},{"key":"e_1_3_4_169_1","author":"Yew WW","year":"2018","unstructured":"Yew WW, Chang KC, Chan DP, et al. Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity. Antimicrob Agents Chemother. 2018\u00a0Jul 27;62(8):e02637\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_170_1","article-title":"Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity","volume":"18","author":"Satyaraddi A","year":"2014","unstructured":"Satyaraddi A, Velpandian T, Sharma SK, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis off J Int Union against Tuberc Lung Dis. 2014;18:188\u2013195, i\u2013iii.","journal-title":"Int J Tuberc Lung Dis off J"},{"key":"e_1_3_4_171_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9829-2"},{"key":"e_1_3_4_172_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku504"},{"key":"e_1_3_4_173_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.987"},{"key":"e_1_3_4_174_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00157914"},{"key":"e_1_3_4_175_1","unstructured":"Liverpool U of. HIV drug interactions [Internet]. [cited 2020 Sep 21]. Available from: https:\/\/www.hiv-druginteractions.org\/checker."},{"key":"e_1_3_4_176_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0716-8"},{"key":"e_1_3_4_177_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4010-7"},{"key":"e_1_3_4_178_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S39747"},{"key":"e_1_3_4_179_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.133173"},{"key":"e_1_3_4_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2012.01.014"},{"key":"e_1_3_4_181_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05150418"},{"key":"e_1_3_4_182_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01988-16"},{"key":"e_1_3_4_183_1","first-page":"1","article-title":"Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment","volume":"42","author":"Strunk A-K","year":"2016","unstructured":"Strunk A-K, Ciesek S, Schmidt JJ, et al. Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2016;42:1\u20133.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"e_1_3_4_184_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12267"},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.04.020"},{"key":"e_1_3_4_186_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002192"},{"key":"e_1_3_4_187_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw471"},{"key":"e_1_3_4_188_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000735"},{"key":"e_1_3_4_189_1","doi-asserted-by":"crossref","first-page":"e01978","DOI":"10.1128\/AAC.01978-19","article-title":"Population pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in pregnant South African women with tuberculosis and HIV","volume":"64","author":"Abdelwahab MT","year":"2020","unstructured":"Abdelwahab MT, Leisegang R, Dooley KE, et al. Population pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in pregnant South African women with tuberculosis and HIV. Antimicrob Agents Chemother. 2020;64:e01978\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_190_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02051-15"},{"key":"e_1_3_4_191_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01724-2016"},{"key":"e_1_3_4_192_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ991"},{"key":"e_1_3_4_193_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170663"},{"key":"e_1_3_4_194_1","article-title":"Challenging the management of drug-resistant tuberculosis","author":"Kim HY","unstructured":"Kim HY, Heysell SK, Mpagama S, et al. Challenging the management of drug-resistant tuberculosis. Lancet. England. 2020 Mar 7;395(10226):783.","journal-title":"Lancet"},{"key":"e_1_3_4_195_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy787"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2021.1836158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:19:32Z","timestamp":1772770772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2021.1836158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,8]]},"references-count":193,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,2]]}},"alternative-id":["10.1080\/17425255.2021.1836158"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2021.1836158","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}